Table 2.
Relative frequencies for transitioning from baseline to endpoint category
| Percentage of patients (duloxetine/placebo) | ||||||
|---|---|---|---|---|---|---|
| Endpoint category | ||||||
| Baseline category | 1 (worst) | 2 (physically poor) | 3 (mentally poor) | 4 (moderate) | 5 (best) | Total no. of patients |
| 1 (worst) | 27.5/42.5** | 25.8/17.2* | 16.6/22.4 | 21.0/9.7** | 9.2/8.2 | 229/134 |
| 2 (physically poor) | 2.9/6.0 | 30.5/41.7* | 7.1/17.2** | 36.4/25.8* | 23.0/9.3** | 239/151 |
| 3 (mentally poor) | 12.8/10.8 | 20.6/24.3 | 13.5/30.6** | 36.2/24.3* | 17.0/9.9 | 141/111 |
| 4 (moderate) | 2.2/3.2 | 20.4/16.1 | 3.2/8.1 | 41.9/50.0 | 32.3/22.6 | 93/62 |
| Total no. of patients | 90/80 | 180/123 | 77/95 | 225/110 | 130/50 | 702/458 |
*p < 0.05, **p < 0.01 for the between-treatment difference in the incidence of transitioning.